In spite of technological advantages in diagnosis and treatment, lung cancer remains one of the most deadly malignant neoplasias. Moreover, there are no markers for monitoring response to treatment. The objective of the study is to associate the number of circulating tumor cells (CTC) before and after treatment and correlate it with tumor response rate, progression-free survival and overall survival.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histopathologic diagnosis of non small-cell lung cancer
Clinical stage IV
ECOG functional status 0 or 1
No renal function alteration (GFR \>50%)
No hepatic function alteration (ALT and AST less than 2 times its normal value)